1. In vitro assessment of the photo(geno)toxicity associated with Lapatinib, a Tyrosine Kinase inhibitor
- Author
-
Ignacio Vayá, Inmaculada Andreu, M Pilar Marín, Miguel A. Miranda, and Guillermo Garcia-Lainez
- Subjects
0301 basic medicine ,BALB 3T3 Cells ,Health, Toxicology and Mutagenesis ,010501 environmental sciences ,Toxicology ,Protein oxidation ,01 natural sciences ,Tyrosine-kinase inhibitor ,Activation, Metabolic ,Protein Carbonylation ,Mice ,QUIMICA ORGANICA ,Epidermal growth factor ,Metabolites ,Cytochrome P-450 CYP3A ,Skin ,Chemistry ,digestive, oral, and skin physiology ,General Medicine ,Protein photooxidation ,Photochemical Processes ,Cellular phototoxicity ,Dealkylation ,Comet Assay ,Phototoxicity ,Tyrosine kinase ,medicine.drug ,medicine.drug_class ,Cell Survival ,Antineoplastic Agents ,Lapatinib ,03 medical and health sciences ,medicine ,Animals ,Humans ,Viability assay ,Photosensitivity Disorders ,Protein Kinase Inhibitors ,Anticancer drug, Cellular phototoxicity, DNA damage, Metabolites, Protein photooxidation ,0105 earth and related environmental sciences ,Anticancer drug ,Fibroblasts ,equipment and supplies ,Comet assay ,Oxidative Stress ,030104 developmental biology ,Cancer research ,DNA damage ,human activities - Abstract
[EN] The epidermal growth factor receptors EGFR and HER2 are the main targets for tyrosine kinase inhibitors (TKIs). The quinazoline derivative lapatinib (LAP) is used since 2007 as dual TKI in the treatment of metastatic breast cancer and currently, it is used as an oral anticancer drug for the treatment of solid tumors such as breast and lung cancer. Although hepatotoxicity is its main side effect, it makes sense to investigate the ability of LAP to induce photosensitivity reactions bearing in mind that BRAF (serine/threonine-protein kinase B-Raf) inhibitors display a considerable phototoxic potential and that afloqualone, a quinazoline-marketed drug, causes photodermatosis. Metabolic bioactivation of LAP by CYP3A4 and CYP3A5 leads to chemically reactiveN-dealkylated (N-LAP) andO-dealkylated (O-LAP) derivatives. In this context, the aim of the present work is to explore whether LAP and itsN- andO-dealkylated metabolites can induce photosensitivity disorders by evaluating their photo(geno)toxicity through in vitro studies, including cell viability as well as photosensitized protein and DNA damage. As a matter of fact, our work has demonstrated that not only LAP, but also its metaboliteN-LAP have a clear photosensitizing potential. They are both phototoxic and photogenotoxic to cells, as revealed by the 3T3 NRU assay and the comet assay, respectively. By contrast, theO-LAP does not display relevant photobiological properties. Remarkably, the parent drug LAP shows the highest activity in membrane phototoxicity and protein oxidation, whereasN-LAP is associated with the highest photogenotoxicity, through oxidation of purine bases, as revealed by detection of 8-Oxo-dG., This study was funded by the Carlos III Institute (ISCIII) of Health (Grants: PI16/01877, CPII16/00052, ARADyAL RD16/0006/0030) co-funded by European Regional Development Fund, the Spanish Government (RYC-2015-17737, CTQ2017-89416-R,) and Generalitat Valenciana (Prometeo/2017/075). We would also like to thank IIS La Fe Microscopy Unit for technical assistance.
- Published
- 2021